ANXA9

Across TCGA pan-cancer cohorts, ANXA9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANXA9 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANXA9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANXA9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where ANXA9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
HNSC	DFS	Tertile	IV	0.914	0.640	.004	5	view →
LUAD	OS	Median	All	0.896	0.783	.022	3	view →
CCRCC	OS	Quartile	All	1.000	0.872	.015	2	view →
LSCC	OS	Median	II,III,IV	0.810	1.000	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANXA9–PDAC (DFS)

Open the PDAC breakdown →